Product Datasheet
www.leinco.com
excellence in early discovery research       




Rabbit Anti-Human Act1 (ACT1)
Purified No Carrier Protein
(ACT1, CIKS, C6orf2, C6orf4, C6orf5, C6orf6, MGC3581, DKFZp586G0522, TRAF3IP2)
Polyclonal Antibody
Share |


Prod. No.:A187
Host:Rabbit
Conc.:0.5 mg/ml
Pkg. Size:0.1 mg, 0.5 mg, 1 mg
Storage:2-8°C Detailed storage instructions below.
Description
Specificity:
Rabbit Anti-Human Act1 recognizes an epitope near the N-terminus of Human Act1. This polyclonal antibody was purified using affinity chromatography.

Background:
Nuclear factor kappa B (NF-κB) is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. NF-κB mediates the expression of a great variety of genes in response to extracellular stimuli. NF-κB associates with IκB proteins in the cell cytoplasm, which inhibit NF-κB activity. IκB is phosphorylated by IκB kinase (IKK) complex that contains IKKα, IKKβ, and IKKγ. A novel molecule that associates with and activates IKK was recently identified and designated CIKS (for connection to IKK and SAPK/JNK) and Act1 (for NF-κB activator 1).1,2 CIKS directly interacts with IKKγ. CIKS/Act1 also activates activating transcription factor (ATF) and activator protein 1 (AP-1) through Jun kinase (JNK). These results indicate that CIKS/Act1 is involved in the inflammation and stress responses. CIKS/Act1 is ubiquitously expressed in human tissues.

Known Species Cross Reactivity: Hu+
Immunogen
Act1 (NT) Blocking Peptide (Leinco Prod. No.: A188)
Blocking Peptide
Act1 (NT) Blocking Peptide (Leinco Prod. No.: A188)
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Stability
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Reported Applications
IHC (NBF/Par.), WB
Each investigator should determine their own optimal working dilution for specific applications.


Country of Origin
USA
References
1. Leonardi, A. et al. (2000) Proc. Natl. Acad. Sci. USA 97(19):10494
2. Li, X. et al. (2000) Proc. Natl. Acad. Sci. USA 97(19):10489
Related Products
Act1 (NT) Blocking Peptide (Leinco Prod. No.: A188)
Act1 (CT) Blocking Peptide (Leinco Prod. No.: A190)
Anti-Human Act1 (CT) (Leinco Prod. No.: A189)
800.538.1145 ® Copyright Leinco Technologies, Inc. 2006 – 2013